Terry Kohler
Known title: CFO and TreasurerCIK: 0001872285
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Verrica to present new YCANTH data at dermatology conferences. Verrica Pharmaceuticals announced it will present new data analysis for its drug YCANTH at two upcoming dermatology conferences. This event allows the company to share recent findings with medical professionals, which is a standard step in communicating clinical progress for its products. The stock currently trades within a wide 52-week range, reflecting the uncertainty often associated with clinical data releases.
Transaction History
| ADMA | ▲ Buy | Grant | 85,130 | $0 | 7/16/2026 | View on chart |
| VRCA | ▼ Sell | Open Market | 7,899 | $19K | 8/27/2024 | View on chart |
| VRCA | ▼ Sell | Open Market | 21,820 | $58K | 8/26/2024 | View on chart |
| VRCA | ▲ Buy | Grant | 40,000 | $0 | 3/15/2024 | View on chart |
| VRCA | ▼ Sell | Open Market | 9,632 | $29K | 11/15/2023 | View on chart |
| VRCA | ▼ Sell | Open Market | 18,452 | $54K | 11/14/2023 | View on chart |
| VRCA | ▲ Buy | Grant | 62,500 | $0 | 8/24/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ADMA Biologics Draws Investor Attention Amid Market Decline
Recent reports indicate that ADMA Biologics is attracting investor attention and showing relative strength while the broader market declines. Analysts have expressed optimism, with an average price target of $17.00, which is well above the current trading range. This suggests that some market participants view the stock as undervalued relative to its long-term potential, despite recent volatility.
ADMA Biologics Draws Investor Attention Amid Market Decline. Recent reports indicate that ADMA Biologics is attracting investor attention and showing relative strength while the broader market declines. Analysts have expressed optimism, with an average price target of $17.00, which is well above the current trading range. This suggests that some market participants view the stock as undervalued relative to its long-term potential, despite recent volatility.